Why the study?
Do angiogenic growth factors have therapeutic potential in the setting of acute myocardial infarction?
Do angiogenic growth factors have therapeutic potential in the setting of acute myocardial infarction?
This review highlights the potential of angiogenic growth factors as a treatment for acute myocardial infarction, potentially through both angiogenic and non-angiogenic mechanisms.
Requires validation in clinical trials before adoption in acute myocardial infarction; extends preclinical findings but leaves translation open.
In models of hind-limb ischemia and progressive coronary artery occlusion, angiogenic growth factor proteins and genes expressing growth factors have been shown to induce the development of collateral vessels and remodeling of existing collaterals. The therapeutic potential of growth factors in the setting of acute myocardial infarction may be related to non-angiogenic properties of growth factors as well, and is the focus of this review.
No takes yet. Share an insight, caveat, or question.
Lino Gonçalves (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: